BioCentury
BioCentury
ARTICLE | Management Tracks

In GSK’s Hoos, Scorpion gains oncology pathfinder to match its $270M war chest  

Departure follows rebuild of pharma’s cancer pipeline

By Jeff Cranmer, Executive Editor
July 7, 2021 11:29 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Scorpion Therapeutics Inc.

GlaxoSmithKline plc

BCIQ Target Profiles

Tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA) (TNFRSF17) (CD269)

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

BCIQ Company Profiles

Scorpion Therapeutics Inc.

GlaxoSmithKline plc

BCIQ Target Profiles

Tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA) (TNFRSF17) (CD269)

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS